ArticleJournal of oncology2022

Efficacy and Safety of Pembrolizumab Monotherapy for Recurrent/Unresectable/Metastatic Oral Squamous Cell Carcinoma: A Single-Center Study in China.

Jieying Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.